149 related articles for article (PubMed ID: 2064307)
1. Inhibition of growth of breast cancer cells in vitro by the ribosome-inactivating protein saporin 6.
Gasperi-Campani A; Zoli W; Volpi A; Roncuzzi L; Amadori D
Anticancer Res; 1991; 11(2):1007-11. PubMed ID: 2064307
[TBL] [Abstract][Full Text] [Related]
2. An immunotoxin composed of monoclonal anti-Thy 1.1 antibody and a ribosome-inactivating protein from Saponaria officinalis: potent antitumor effects in vitro and in vivo.
Thorpe PE; Brown AN; Bremner JA; Foxwell BM; Stirpe F
J Natl Cancer Inst; 1985 Jul; 75(1):151-9. PubMed ID: 3859688
[TBL] [Abstract][Full Text] [Related]
3. Cytotoxic activity of an anti-transferrin receptor immunotoxin on normal and leukemic human hematopoietic progenitors.
Cazzola M; Bergamaschi G; Dezza L; D'Uva R; Ponchio L; Rosti V; Ascari E
Cancer Res; 1991 Jan; 51(2):536-41. PubMed ID: 1985771
[TBL] [Abstract][Full Text] [Related]
4. In vitro potentiation by lonidamine of the sc-RIP saporin 6 effect in a human metastatic breast cancer cell line.
Roncuzzi L; Zoli W; Bajorko P; Gasperi-Campani A
Anticancer Res; 1995; 15(3):773-6. PubMed ID: 7645957
[TBL] [Abstract][Full Text] [Related]
5. Differential activity of saporin 6 on normal and leukemic hemopoietic cells.
Gasperi-Campani A; Zauli G; Roncuzzi L; Valvassori L; Vitale L; Gaggioli L; Bagnara GP
Exp Hematol; 1989 Aug; 17(7):755-9. PubMed ID: 2753083
[TBL] [Abstract][Full Text] [Related]
6. Shock wave permeabilization with ribosome inactivating proteins: a new approach to tumor therapy.
Delius M; Adams G
Cancer Res; 1999 Oct; 59(20):5227-32. PubMed ID: 10537301
[TBL] [Abstract][Full Text] [Related]
7. Immunotoxin-mediated inhibition of chronic lymphocytic leukemia cell proliferation in humans.
Siena S; Bregni M; Formosa A; Brando B; Marenco P; Lappi DA; Bonadonna G; Gianni AM
Cancer Res; 1989 Jun; 49(12):3328-32. PubMed ID: 2785850
[TBL] [Abstract][Full Text] [Related]
8. In vitro bone marrow purging of multidrug-resistant cells with a mouse monoclonal antibody directed against Mr 170,000 glycoprotein and a saporin-conjugated anti-mouse antibody.
Dinota A; Tazzari PL; Michieli M; Visani G; Gobbi M; Bontadini A; Tassi C; Fanin R; Damiani D; Grandi M
Cancer Res; 1990 Jul; 50(14):4291-4. PubMed ID: 1694719
[TBL] [Abstract][Full Text] [Related]
9. In vitro and in vivo efficacy of heat shock protein specific immunotoxins on human tumor cells.
Piselli P; Vendetti S; Poccia F; Cicconi R; Mattei M; Bolognesi A; Stirpe F; Colizzi V
J Biol Regul Homeost Agents; 1995; 9(2):55-62. PubMed ID: 9127634
[TBL] [Abstract][Full Text] [Related]
10. An immunotoxin made up with campath 1 and saporin 6: preliminary "in vitro" experience.
Gobbi M; Barbieri L; Tazzari PL; Dinota A; Bontadini A; Rizzi S; Pession A; Stirpe F; Tura S
J Exp Pathol; 1987; 3(4):359-62. PubMed ID: 3331647
[No Abstract] [Full Text] [Related]
11. Saporin 6 and lonidamine in primary cell cultures from human breast carcinomas: a synergistic effect.
Gasperi-Campani A; Roncuzzi L; Zoli W; Amadori D
Anticancer Drug Des; 1997 Mar; 12(2):91-8. PubMed ID: 9113064
[TBL] [Abstract][Full Text] [Related]
12. Delivery of saporin to human B-cell lymphoma using bispecific antibody: targeting via CD22 but not CD19, CD37, or immunoglobulin results in efficient killing.
Bonardi MA; French RR; Amlot P; Gromo G; Modena D; Glennie MJ
Cancer Res; 1993 Jul; 53(13):3015-21. PubMed ID: 7686448
[TBL] [Abstract][Full Text] [Related]
13. Therapy of human T-cell acute lymphoblastic leukaemia with a combination of anti-CD7 and anti-CD38-SAPORIN immunotoxins is significantly better than therapy with each individual immunotoxin.
Flavell DJ; Boehm DA; Noss A; Warnes SL; Flavell SU
Br J Cancer; 2001 Feb; 84(4):571-8. PubMed ID: 11207056
[TBL] [Abstract][Full Text] [Related]
14. Diverse activity of sc-RIP saporin 6 on primary and metastatic melanoma cells in vitro.
Gasperi-Campani A; Musa AR; Roncuzzi L
Melanoma Res; 1993 Oct; 3(5):363-7. PubMed ID: 8292894
[TBL] [Abstract][Full Text] [Related]
15. Bispecific F(ab' gamma)2 antibody for the delivery of saporin in the treatment of lymphoma.
Glennie MJ; Brennand DM; Bryden F; McBride HM; Stirpe F; Worth AT; Stevenson GT
J Immunol; 1988 Nov; 141(10):3662-70. PubMed ID: 3141503
[TBL] [Abstract][Full Text] [Related]
16. CD38 as a target of IB4 mAb carrying saporin-S6: design of an immunotoxin for ex vivo depletion of hematological CD38+ neoplasia.
Bolognesi A; Polito L; Farini V; Bortolotti M; Tazzari PL; Ratta M; Ravaioli A; Horenstein AL; Stirpe F; Battelli MG; Malavasi F
J Biol Regul Homeost Agents; 2005; 19(3-4):145-52. PubMed ID: 16602630
[TBL] [Abstract][Full Text] [Related]
17. Antitumor activity of basic fibroblast growth factor-saporin mitotoxin in vitro and in vivo.
Beitz JG; Davol P; Clark JW; Kato J; Medina M; Frackelton AR; Lappi DA; Baird A; Calabresi P
Cancer Res; 1992 Jan; 52(1):227-30. PubMed ID: 1309225
[TBL] [Abstract][Full Text] [Related]
18. Cooperative mixtures of bispecific F(ab')2 antibodies for delivering saporin to lymphoma in vitro and in vivo.
French RR; Courtenay AE; Ingamells S; Stevenson GT; Glennie MJ
Cancer Res; 1991 May; 51(9):2353-61. PubMed ID: 2015599
[TBL] [Abstract][Full Text] [Related]
19. Induction of apoptosis by ribosome-inactivating proteins and related immunotoxins.
Bolognesi A; Tazzari PL; Olivieri F; Polito L; Falini B; Stirpe F
Int J Cancer; 1996 Nov; 68(3):349-55. PubMed ID: 8903477
[TBL] [Abstract][Full Text] [Related]
20. Immunotoxins containing saporin linked to different CD2 monoclonal antibodies: in vitro evaluation.
Tazzari PL; Bolognesi A; De Totero D; Lemoli RM; Fortuna A; Conte R; Crumpton MJ; Stirpe F
Br J Haematol; 1994 Jan; 86(1):97-105. PubMed ID: 7912101
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
